Dyne Therapeutics, Inc. (DYN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.79 |
| Open | 8.90 |
| Bid | 8.59 x 800 |
| Ask | 9.36 x 800 |
| Day's Range | 8.65 - 9.07 |
| 52 Week Range | 8.04 - 15.60 |
| Volume | |
| Avg. Volume | 419,569 |
| Market Cap | 546.744M |
| Beta (5Y Monthly) | 0.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.55 |
| Earnings Date | Nov 01, 2023 - Nov 06, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 29.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for DYN
Related Research
- Dyne Therapeutics, Inc.Analyst Report: Xcel Energy Inc.Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan; Public Service Company of Colorado; and Southwestern Public Service Company, which serves customers in Texas and New Mexico. It is one of the largest renewable energy providers in the U.S. with half of its electricity sales coming from carbon-free energy.RatingFair ValueEconomic Moatlast monthMorningstar
GlobeNewswireDyne Therapeutics to Present at October Investor Conferences
WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in October: Chardan’s 7th Annual Genetic Medicines Conference, fireside chat on Tuesday, October 3, 2023 at 11:00 a.m. ET in New York Jefferies Inaugural Biotech
- GlobeNewswire
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
- On Track to Report Initial Data from the Global, Multiple Ascending Dose Phase 1/2 ACHIEVE Clinical Trial in the Second Half of 2023 - WALTHAM, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for DYNE-101 for
Motley FoolWhy Shares of Dyne Therapeutics Fell This Week
The clinical-stage biotech's stock closed at $10.98 last week, then fell to as low as $8.57 this Friday, thanks to a number of insiders selling their shares. On Wednesday the company released six filings with the Securities and Exchange Commission (SEC), all showing selling by company executives on Tuesday. According to the filings, president and CEO Joshua Brumm sold 7,622 shares, chief operating officer Susanna High sold 1,635 shares, chief medical officer Wildon Farwell sold 1,707 shares, chief scientific officer Oxana Beskrovnaya sold 1,484 shares, chief business officer Jonathan McNeill sold 1,266 shares, and senior vice president Richard Scalzo sold 1,397 shares.
